January 1, 2019Open Access

Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption

Key Points

Key points are not available for this paper at this time.

Abstract

: Advanced therapeutic medicinal therapies are still in their early days, but constantly evolving. By 2020, innovative therapies targeting retinal dystrophy, ß-thalassemia, scleroderma, sickle-cell anaemia, adrenoleukodystrophy and leukaemia shall be available on the market.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Eder et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69ff725bef8139f8ff775d46 — DOI: https://doi.org/10.1080/20016689.2019.1600939

Authors

Claudia Eder

Claudia Wild

Journals

Journal of Market Access & Health Policy

Actions

Institutions

Austrian Institute for Health Technology Assessment GmbH

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider